WO2021134935A1 - Utilisation de cannabidiol dans la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale - Google Patents

Utilisation de cannabidiol dans la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale Download PDF

Info

Publication number
WO2021134935A1
WO2021134935A1 PCT/CN2020/081112 CN2020081112W WO2021134935A1 WO 2021134935 A1 WO2021134935 A1 WO 2021134935A1 CN 2020081112 W CN2020081112 W CN 2020081112W WO 2021134935 A1 WO2021134935 A1 WO 2021134935A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
cannabidiol
preparation
pharmaceutically acceptable
keratinocytes
Prior art date
Application number
PCT/CN2020/081112
Other languages
English (en)
Chinese (zh)
Inventor
袁泉
柯博文
于朝晖
常坦然
赵丽梅
Original Assignee
四川大学
云南汉盟制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 四川大学, 云南汉盟制药有限公司 filed Critical 四川大学
Publication of WO2021134935A1 publication Critical patent/WO2021134935A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Definitions

  • This application relates to the field of drug applications, in particular to a new strategy for promoting the healing of the oral mucosa, and in particular to the application of cannabidiol in the preparation of drugs for promoting the healing of the oral mucosa.
  • Inflammatory lesions of the oral mucosa involving the epithelium and subepithelial connective tissue (lamina propria), are severely painful, and can seriously affect the patient's quality of life. It is the result of multiple factors with unknown etiology. There is no stable and effective treatment at present.
  • the clinical treatment is mostly symptomatic treatment, mainly to relieve pain and promote healing, such as oral cavity washing, local or systemic use of analgesics, hormones, etc. .
  • scholars have successively proposed the use of growth factors, anti-inflammatory substances, immunomodulators, anti-radiation drugs, etc. for prevention and treatment, most of which are still in the preclinical stage, and most growth factors have the potential to promote the growth of cancer cells.
  • CN101468039B discloses a preparation method of a compound double-layer sustained-release medicinal film for the treatment of oral mucosal diseases, which is based on borneol, artificial bezoar, tinidazole, dyclonine hydrochloride, tween-80, glycerin, sodium saccharin, and carboxymethyl It is made of raw materials such as sodium cellulose and polyvinyl alcohol.
  • the compound double-layer sustained-release medicinal film overcomes the shortcomings of single-layer and single-layer films of Chinese and Western medicine, is durable and has obvious curative effect, and has the effect of promoting the healing of oral lesions. Compared with the single-layer film, the double-layer film changes from a single-layer drug release to a double-layer drug release, so that the drug is limited to local contact with the diseased part, reducing the drug outflow and reducing the peculiar smell of oral drugs.
  • CN104189165A discloses a traditional Chinese medicine preparation for oral mucosal ulcers.
  • the mass ratio of each component in the formula is: rhubarb 500-700g; Glauber's salt 500-700g; licorice 500-700g; gardenia 200-400g; scutellaria 200-400g ; Mint 200 ⁇ 400g; Forsythia 1100 ⁇ 1300g. It acts directly on the mucous membranes, has fast drug absorption, and has obvious curative effects. It has the characteristics of good biocompatibility, prevention of exudate overflow, hemostasis and pain relief, anti-inflammatory and antibacterial, and promotes the formation of granulation tissue and mucosal tissue, and fast healing and repair of skin and mucosal tissue.
  • CN106692201A discloses a composition for preventing and treating radiation oral mucositis and its application.
  • the composition includes mussel soft tissue extract and fungal polysaccharide.
  • the composition for preventing and treating radiation oral mucositis of the present application can block radiation damage caused by exogenous factors, has a super anti-radiation effect, prevents oral mucositis, promotes the regeneration and repair of oral mucosal tissues, shortens wound healing time, and reduces inflammation Pain relief.
  • This application is mild, non-irritating, non-toxic and side-effect, and non-use-dependent.
  • the main active ingredient in cannabis leaf extract is cannabinoids.
  • the cannabinoids isolated from the cannabis plant are tetrahydrocannabinol (THCV), cannabidiol (CBD), cannabidiol (CBDV), and cannabidiol ( CBG) and so on.
  • THCV tetrahydrocannabinol
  • CBD cannabidiol
  • CBDV cannabidiol
  • CBG cannabidiol
  • cannabidiol as a non-psychological component, has medicinal value in anti-tumor, nervous system protection, immune regulation, anti-inflammatory and antioxidant properties.
  • researchers have made great progress in the pharmacological research of cannabinoids and the development and utilization of drugs, but there is very little research in the field of oral cavity, especially in promoting the healing of oral mucosa.
  • the purpose of this application is to provide a new strategy for promoting the healing of the oral mucosa, in particular to provide the application of cannabidiol in the preparation of medicines for promoting the healing of the oral mucosa.
  • this application provides the use of cannabidiol or its pharmaceutically acceptable salts, esters, and solvates in the preparation of drugs for promoting oral mucosal healing.
  • cannabidiol or its pharmaceutically acceptable salts, esters, and solvates can be used in the preparation of drugs that promote oral mucosal healing, through the exploration of the effect of cannabidiol on the biological behavior of human oral keratinocytes
  • the investigation of the therapeutic effect of oral ulcer model mice found that it has a significant effect on promoting proliferation and migration of oral mucosal keratinocytes and inhibiting excessive pyrolysis of oral mucosal keratinocytes, and these three effects are concentration and time dependent; It has a significant effect on promoting the healing of oral mucosa of oral ulcer model mice; analysis of transcriptome sequencing technology found that it has a tendency to down-regulate most of the genes in keratinocytes that induce inflammation, especially the activation of NLRP3 inflammasomes and pyrolysis All related genes have a significant down-regulation effect.
  • the drug promotes proliferation of oral keratinocytes.
  • the drug promotes the migration of oral keratinocytes.
  • the drug inhibits oral keratinocyte pyrolysis.
  • the drug inhibits the NLRP3 inflammasome activation pathway.
  • this application provides the use of cannabidiol or its pharmaceutically acceptable salts, esters, and solvates in the preparation of oral keratinocyte proliferation promoters.
  • this application provides the use of cannabidiol or its pharmaceutically acceptable salts, esters, and solvates in the preparation of oral keratinocyte migration promoters.
  • this application provides the use of cannabidiol or its pharmaceutically acceptable salts, esters, and solvates in the preparation of oral keratinocyte pyrolysis inhibitors.
  • the oral keratinocyte pyrolysis inhibitor here means that cannabidiol or its pharmaceutically acceptable salts, esters, and solvates can inhibit the excessive pyrolysis of oral keratinocytes in the process of relieving inflammation and promoting healing, rather than Refers to the complete suppression of scorch.
  • this application provides the use of cannabidiol or its pharmaceutically acceptable salts, esters, and solvates in the preparation of NLRP3 inflammasome activation pathway inhibitors.
  • the medicine may also include pharmaceutically acceptable excipients.
  • the auxiliary material includes any one or a combination of at least two of diluents, carriers, flavoring agents, binders or fillers, such as a combination of binders and diluents, The combination of carrier and flavoring agent, combination of binder and filler, etc., and other arbitrary combinations will not be repeated here.
  • the carrier includes liposomes, micelles, dendrimers, microspheres or microcapsules.
  • cannabidiol or its pharmaceutically acceptable salts, esters, and solvates described in this application can be loaded on common medicinal carriers as drugs to promote oral mucosal healing to achieve better biocompatibility, targeting, Biological safety and drug delivery effect.
  • cannabidiol or its pharmaceutically acceptable salts, esters, and solvates described in this application can also be used in combination with other drugs to achieve a better effect of promoting oral mucosal healing.
  • the dosage form of the drug includes tablets, capsules, granules, powders, injections, sprays, films, suppositories, nose drops or pills, preferably oral sprays.
  • Drugs using cannabidiol or its pharmaceutically acceptable salts, esters, or solvates as the active ingredient can be prepared into any of the above-mentioned pharmaceutical dosage forms according to actual needs, and the drugs of each dosage form can be carried out according to conventional methods in the pharmaceutical field. preparation.
  • the route of administration of the drug can be selected from oral administration, sublingual administration, intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral spray administration or transdermal administration according to actual needs.
  • oral administration sublingual administration, intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral spray administration or transdermal administration according to actual needs.
  • Figure 1 is the result of the proliferation-promoting effect of cannabidiol on human oral keratinocytes (in the figure, CBD-0, CBD-0.5, CBD-2, CBD-10, CBD-50 represent the concentration of 0, 0.5, 2, 10. The result of 50 ⁇ mol/L cannabidiol culture medium);
  • Figure 2 is the result of the effect of cannabidiol on the migration promotion of human oral keratinocytes (from top to bottom, from left to right in the figure represents the administration of cannabidiol at concentrations of 0, 0.5, 2, 10, and 50 ⁇ mol/L Scratch cell migration after 0h, 24h, 48h);
  • Figure 3A is a graph showing the results of the inhibitory effect of cannabidiol on human oral keratinocytes on pyrolysis ( Figure 3A represents the ratio of pyrolysis after treatment with cannabidiol and 50 ⁇ mol/L cannabidiol);
  • Figure 3B is the result of the inhibitory effect of cannabidiol on human oral keratinocytes on pyrolysis ( Figure 3B is the result of statistical analysis of the results of Figure 3A);
  • Figure 4 is a graph showing the effect of cannabidiol on the body weight of mice
  • Figure 5 is a graph showing the effect of cannabidiol on the healing of oral mucosa in mice
  • Figure 6 is the results of HE staining of mouse oral tissues (where (a), (b), (c) represent the HE staining results of the negative control group, low concentration drug group, and high concentration drug group, respectively);
  • Figure 7 is the results of EDU staining of mouse oral tissue (where (a), (b), (c) represent the EDU staining results of the negative control group, the low-concentration drug group, and the high-concentration drug group, respectively);
  • Figure 8 is the results of immunofluorescence staining of mouse oral tissue (where (a), (b), (c) represent the immunofluorescence staining results of the negative control group, low concentration drug group, and high concentration drug group, respectively);
  • Figure 9A is a graph of the results of transcriptome sequencing analysis (A is a graph of differential gene expression in cells after administration of cannabidiol);
  • Figure 9B is a graph of the results of transcriptome sequencing analysis (B is a graph of the enrichment results of NLRP3 inflammasome activation and pyrolysis-related gene sets).
  • the source of the drug cannabidiol is: Yunnan Hanmeng Pharmaceutical Co., Ltd. self-made sample;
  • mice were purchased from Shanghai Southern Model Biotechnology Co., Ltd., 250-350g, male, all operations on mice were performed in a sterile laminar flow chamber;
  • Oral keratinocytes (immortalized human oral keratinocytes HOK-16B cultured in SFM medium containing keratinocyte growth factor) were purchased from the No-Hee Park laboratory of the University of California, Los Angeles.
  • the CCK-8 method is used to detect the viability of oral keratinocytes.
  • the operation method is: prepare a cell suspension, count the cells; inoculate into a 96-well plate, the number of cells per well is about 5000/mL, each group has 3 auxiliary wells, each well Add 100 ⁇ L of culture fluid; incubate in a 37°C incubator for 24 hours. Then change to a medium containing different concentrations of cannabidiol (0, 0.5, 2, 10, 50 ⁇ mol/L) after culturing for 24, 48, 72, and 96 hours, and then use the CCK8 kit to detect the proliferation of oral keratinocytes in different groups (The specific operation steps are carried out in accordance with the kit instructions).
  • cannabidiol has an effect of significantly promoting the proliferation of oral keratinocytes, and the effect of cannabidiol on the proliferation of oral keratinocytes is significantly concentration-dependent and time-dependent.
  • the cell scratch test detects the migration behavior of oral keratinocytes.
  • the operation method is: prepare a cell suspension and count the cells; inoculate oral keratinocytes HOK-16B in a 12-well plate, the number of cells per well is about 1 ⁇ 10 5 mL, each Set up 3 auxiliary wells, add 800 ⁇ L of culture medium to each well; after culturing overnight in a 37°C incubator, the bottom of the well plate is covered with a single layer of keratinocytes. Use a 200 ⁇ l pipette tip to make cell scratches perpendicular to the bottom of the well plate (try to ensure that the width of each scratch is the same).
  • the original culture medium was aspirated, washed three times with PBS, and replaced with serum-free medium containing different concentrations of cannabidiol (0, 0.5, 2, 10, 50 ⁇ mol/L), and photographed and recorded. Incubate in a 5% CO2, 37°C incubator, and take pictures every 24 hours.
  • cannabidiol has the effect of significantly promoting the migration of oral keratinocytes, and its promotion effect is positively correlated with the concentration.
  • Annexin V-FITC detects oral keratinocyte pyrolysis
  • the operation method is: prepare cell suspension, cell count; inoculate oral keratinocyte HOK-16B in 6-well plate, add different concentrations (0, 50 ⁇ mol/L)
  • the culture medium of cannabidiol is incubated in a 5% CO2, 37°C incubator.
  • the Annexin V-FITC cell pyroptosis detection kit was used to detect the pyroptosis rate (the specific operation steps were carried out in accordance with the kit instructions).
  • Fig. 3A and Fig. 3B The results are shown in Fig. 3A and Fig. 3B: the pyrolysis rate of HOK-16B cells after 50 ⁇ mol/L cannabidiol was lower than that of the adjuvant control group without cannabidiol (the Q2 and Q3 quadrants in Fig. 3A represent the early and late pyroptosis ⁇ cells), and it can be seen from Figure 3B that the difference between the two is statistically significant.
  • mice Female mice (250-350g) were placed in a plastic cage and fed normally for 5 days to adapt to the environment of the animal experiment center. Randomly divide into 3 groups, each with 30 animals. After the three groups of mice were anesthetized by intraperitoneal injection, a 5mm inner diameter circumcision drill was used to directly drill the mucosal tissue of the back of the tongue, resulting in a defect of about 5mm in diameter and about 1mm in depth, and continued to be given a high-viscosity diet. Ulcers formed one day after modeling .
  • Evaluation indicators include the following:
  • the method of operation is as follows: from the day of oral ulcer modeling, daily monitoring of the changes in body weight of mice in each group. The results are shown in Figure 4: As the course of the disease progresses, the weight of the mice first drops and then rises. There is no significant difference in weight change between the low-concentration administration group and the control group, and the weight recovery of the high-concentration administration group is faster.
  • the method of operation is as follows: From the day of oral ulcer modeling, measure the maximum diameter (D) and minimum diameter (d) of the oral ulcer lesion every day, and record the ulcer size as the average of the two. The results are shown in Figure 5. It can be seen from the figure that the size of the ulcer is significantly reduced after the local spray treatment of cannabidiol, that is, the oral mucosa is promoted after administration, and the healing effect of the high concentration group is more significant than that of the low concentration group.
  • the operation method is: after routine dewaxing of the paraffin sections of the tongue tissue, staining with hematoxylin, washing with water and staining with eosin, dehydrating the section with gradient alcohol, sealing the slide with neutral gum after transparency, observing and taking pictures under an inverted microscope.
  • the operation method is: two hours before the collection of the sample, the mouse is injected with EDU into the abdominal cavity, two hours later, the sample is collected, and the tissue is made into paraffin sections. After routine deparaffinization, 0.5% TritonX-100 ruptures the tissue. After EDU is incubated at room temperature for 30 minutes in the dark, DAPI recovers Stain cell nuclei, mount the slides, observe and take pictures under a fluorescence microscope.
  • the method of operation is: fix the tongue tissue after sampling, make tissue paraffin sections, after routine deparaffinization, sodium citrate antigen heat repair, hydrogen peroxide inhibits endogenous peroxisomes, incubate the primary antibody overnight at 4°C. Incubate the secondary antibody at 37°C for 1 hour, counter-stain the cell nucleus with DAPI, mount the slide, observe under a fluorescent microscope, and take pictures.
  • Transcriptome sequencing technology was used to analyze the changes in related genes after inflammatory-stimulated oral keratinocytes were treated with cannabidiol.
  • the specific operation method is as follows: prepare a cell suspension and count the cells; inoculate oral keratinocytes HOK-16B in a 6-well plate, incubate in a 5% CO2, 37°C incubator for 18 hours, and give LPS (100ng/mL) for 6 hours After adding different concentrations of (0, 50 ⁇ mol/L) cannabidiol for 2h, and finally adding ATP (4mM) for 30min, the cells were collected, and total RNA was extracted for transcriptome sequencing analysis.
  • the abscissa represents the multiple of the difference, plus or minus represents up and down, the larger the absolute value, the greater the multiple of the difference; the ordinate represents the adjusted P value, the larger the value, the more significant the difference, so the horizontal and vertical in the figure
  • the area separated by the dotted line, that is, the upper left grid and the upper right grid are considered to be genes that are significantly down-regulated and significantly up-regulated after treatment with cannabidiol).
  • the administration group listed in Figure 9B has significantly down-regulated genes related to NLRP3 inflammasome activation and pyrolysis (CK1-3 is the administration group, NC1-3 is the control group, and the color ranges from light to Deep is the expression from low to high).

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de cannabidiol ou d'un sel, ester et solvate pharmaceutiquement acceptable correspondant dans la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale. L'application du cannabidiol ou du sel, ester et solvant pharmaceutiquement acceptable correspondant pour la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale présente des effets significatifs de stimulation de la prolifération et de la migration de kératinocytes de la muqueuse buccale et de suppression de la pyroptose excessive des kératinocytes de la muqueuse buccale, présente un effet significatif de stimulation de la cicatrisation de la muqueuse buccale de souris d'un modèle d'ulcère buccal et présente un effet de régulation à la baisse, découvert par analyse à l'aide de la technologie de séquençage du transcriptome, sur la plupart des gènes dans les kératinocytes qui induisent une inflammation et présente en particulier un effet de régulation à la baisse évident sur des gènes associés à l'activation et à la pyroptose d'inflammasomes NLRP3.
PCT/CN2020/081112 2019-12-31 2020-03-25 Utilisation de cannabidiol dans la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale WO2021134935A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911418931.2A CN113116870A (zh) 2019-12-31 2019-12-31 大麻二酚在制备促进口腔黏膜愈合的药物中的应用
CN201911418931.2 2019-12-31

Publications (1)

Publication Number Publication Date
WO2021134935A1 true WO2021134935A1 (fr) 2021-07-08

Family

ID=76685835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/081112 WO2021134935A1 (fr) 2019-12-31 2020-03-25 Utilisation de cannabidiol dans la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale

Country Status (2)

Country Link
CN (1) CN113116870A (fr)
WO (1) WO2021134935A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111424A1 (fr) * 2005-04-22 2006-10-26 Life & Brain Gmbh Procedes permettant d'identifier des modulateurs des recepteurs cannabinoides cb1 et cb2 et leur utilisation dans la cicatrisation des blessures
WO2018222923A1 (fr) * 2017-05-31 2018-12-06 Phytecs, Inc. Compositions pharmaceutiques comprenant du cannabidiol et du bêta-caryophyllène et leurs procédés d'utilisation
CN109642215A (zh) * 2016-06-15 2019-04-16 奥海能量公益公司 用于增强干细胞疗法的方法和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203976A1 (en) * 2009-11-24 2013-05-02 Alder Biopharmaceuticals, Inc Antibodies to IL-6 and use thereof
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
WO2017190249A1 (fr) * 2016-05-04 2017-11-09 Inmed Pharmaceuticals Inc. Utilisation de formulations topiques de cannabinoïdes pour le traitement de l'épidermolyse bulleuse et de troubles du tissu conjonctif connexes
CN109939014A (zh) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 一种含有大麻素的口气清新剂
CN109939033A (zh) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 一种含有大麻素的漱口水及其制备方法
CN109939011A (zh) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 一种含有大麻素的牙膏及其制备方法
WO2019155389A1 (fr) * 2018-02-06 2019-08-15 Target Oncology Inc. Composition mucoadhésive et bioadhésive aqueuse destinée au traitement
CN109528583A (zh) * 2018-12-17 2019-03-29 云南汉木森生物科技有限责任公司 一种抗菌消炎止痛漱口水及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111424A1 (fr) * 2005-04-22 2006-10-26 Life & Brain Gmbh Procedes permettant d'identifier des modulateurs des recepteurs cannabinoides cb1 et cb2 et leur utilisation dans la cicatrisation des blessures
CN109642215A (zh) * 2016-06-15 2019-04-16 奥海能量公益公司 用于增强干细胞疗法的方法和组合物
WO2018222923A1 (fr) * 2017-05-31 2018-12-06 Phytecs, Inc. Compositions pharmaceutiques comprenant du cannabidiol et du bêta-caryophyllène et leurs procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG YUANLING, WAN TING, PANG NENGZHI, ZHOU YUJIA, JIANG XUYE, LI BANGYAN, GU YINGYING, HUANG YUFENG, YE XIAODIE, LIAN HUI, ZHANG: "Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high‐fat high cholesterol diet via regulating NF‐κB and NLRP3 inflammasome pathway", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC., US, vol. 234, no. 11, 1 November 2019 (2019-11-01), US, pages 21224 - 21234, XP055826000, ISSN: 0021-9541, DOI: 10.1002/jcp.28728 *
KLEIN M; DE QUADROS DE BORTOLLI J; GUIMARÃES F S; SALUM F G; CHERUBINI K; DE FIGUEIREDO M A Z: "Effects of cannabidiol, a Cannabis sativa constituent, on oral wound healing process in rats: Clinical and histological evaluation", PHYSIOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER., GB, 1 June 2018 (2018-06-01), GB, pages 2275 - 2281, XP018533182, ISSN: 0951-418X *
L. F. CUBA, F. G. SALUM, K. CHERUBINI, M. A. Z. FIGUEIREDO: "Cannabidiol: an alternative therapeutic agent for oral mucositis?", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS., BLACKWELL SCIENTIFIC PUBLICATION, OXFORD., GB, vol. 42, no. 3, 1 June 2017 (2017-06-01), GB, pages 245 - 250, XP055511648, ISSN: 0269-4727, DOI: 10.1111/jcpt.12504 *

Also Published As

Publication number Publication date
CN113116870A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
CN106798737A (zh) 用于防治肺纤维化的隐丹参酮类及其应用
Ma et al. Anemoside B4 prevents chronic obstructive pulmonary disease through alleviating cigarette smoke-induced inflammatory response and airway epithelial hyperplasia
WO2021134935A1 (fr) Utilisation de cannabidiol dans la préparation de médicaments pour stimuler la cicatrisation de la muqueuse buccale
CN113940945A (zh) 鱼腥草多糖在制备防治炎症性肠病药物中的用途
CN115192573B (zh) 盐酸去亚甲基小檗碱在制备治疗肺纤维化药物中的应用
CN109419787B (zh) 一种松香烷型二萜类化合物的用途
CN114796195A (zh) 淫羊藿素在制备脂多糖诱导急性肺损伤保护药物组合物中的应用
TW202002987A (zh) 人參皂苷m1用於治療口腔癌之用途
CN103919757B (zh) 紫草萘醌类化合物的医药用途
CN113018365A (zh) 一种复方龙血竭口腔溃疡药物组合物及其制备方法
CN113908149A (zh) 刺芒柄花素在制备防治急性肺损伤药物中的用途
CN102247349B (zh) 丹酚酸a预防和/或治疗糖尿病所致肝脏病变的用途
CN107412647B (zh) 一种灭菌止痒留香的外用制剂
KR20210087999A (ko) 클로날 줄기세포를 포함하는 아토피 피부염 예방 또는 치료용 약학적 조성물
US20100048457A1 (en) Glycoprotein for treating chronic obstructive pulmonary diseases
CN116549434A (zh) 淫羊藿素在制备弹性蛋白酶和脂多糖联合诱导慢性阻塞性肺疾病药物组合物中的应用
CN104940177B (zh) 藤黄酮f的医药用途
CN110448682B (zh) 一种用于湿疹治疗的外用药物及其制备方法和应用
CN110833550B (zh) 吡唑并嘧啶衍生物在治疗急性胰腺炎致肝损伤的用途
CN115708840A (zh) 神香草提取物在制备抗肺癌药物中的应用
CN116637117A (zh) 异连翘酯苷在制备乳腺癌治疗药物中的应用
CN103919756B (zh) 紫草萘醌类化合物的医药用途
CN103919769A (zh) 去甲蟛蜞菊内酯-7-硫酸酯在制备抗肺纤维化药物中的应用
CN116687907A (zh) 淫羊藿素在制备抑制淀粉样蛋白Aβ诱导阿尔兹海默病药物中的应用
CN117257798A (zh) 小檗碱在预防主动脉夹层动脉瘤进展中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20910824

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20910824

Country of ref document: EP

Kind code of ref document: A1